Endocrine System Disorders
Endocrine system disorders are a group of conditions that affect the normal functioning of endocrine glands, which include, but are not limited to, the thyroid, adrenal glands, pituitary gland, and gonads. These disorders are usually associated with abnormal hormone production, which may be either too high or too low, resulting in an imbalance in a variety of physiological functions in the body.
Common endocrine system disorders include diabetes mellitus, thyroid dysfunction (including hyperthyroidism and hypothyroidism), adrenal disorders (e.g., Addison's disease and Cushing's syndrome), pituitary dysfunction, gonadal disorders (e.g., polycystic ovary syndrome), osteoporosis, and obesity.
Drug research for endocrine system disorders has multiple targets and therapeutic strategies for different diseases and pathomechanisms. The following are some of the major disease drug development advances and their corresponding targets:
- Diabetes: The main targets for drug development in diabetes include insulin secretion, insulin resistance, GLP-1 receptor, SGLT2, etc. GLP-1 receptor agonists (e.g., liraglutide), SGLT2 inhibitors (e.g., dalgreiforme), and novel insulin analogs have been developed, which lower the blood glucose level through different mechanisms.
- Thyroid Diseases: The main targets for drug development for thyroid diseases include thyroid hormone synthesis, thyroid hormone receptors, and TSH receptors. Beta-blockers (e.g., propranolol) and antithyroid drugs (e.g., methimazole) are currently used in the treatment of hyperthyroidism. Treatment of hypothyroidism relies on thyroid hormone replacement therapy.
- Cushing's Syndrome: Cushing's Syndrome drug development primarily targets cortisol synthesis and cortisol receptors. Treatment may include the use of cortisol synthesis inhibitors (e.g., ketoconazole) and cortisol receptor antagonists (e.g., mifepristone).
- Growth Hormone Abnormalities: Growth Hormone Abnormalities Drug development primarily targets growth hormone secretion and growth hormone receptors. Growth hormone deficiency is treated with recombinant human growth hormone, while acromegaly may be treated with growth hormone receptor antagonists (e.g., pegvisomant).
- Obesity: Growth hormone abnormality drug development is aimed at appetite control, energy expenditure, and fat absorption. Novel drugs (e.g., Semelatide) reduce hunger and food intake by mimicking the effects of GLP-1.
Endocrine System Disorders Drug Targets
Endocrine System Disorders Drug Target Related Products
● Target Proteins
Measured by its binding ability in a functional ELISA. Immobilized Human GLP1R at 2 μg/mL can bind Anti-GLP1R recombinant antibody (CSB-RA009514MA1HU), the EC50 is 54.54-94.23 ng/mL.
Human GH1 protein his/myc tag (CSB-MP009407HU) captured on COOH chip can bind Human GHR protein Fc tag (CSB-MP009411HU) with an affinity constant of 6.1 nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized PD-1 at 2 μg/ml can bind Anti-PD-1 recombinant antibody, the EC50 of human PD-1 protein is 6.087-7.854 ng/ml.
-AC1.jpg)
Measured by its binding ability in a functional ELISA. Immobilized human CLDN18.2 (CSB-MP005498HU(A5)) at 5 μg/ml can bind anti-CLDN18.2 recombinant Monoclonal Antibody (CSB-RA005498A1HU), the the EC50 is 5.225-9.256 ng/ml.
Human EGF protein captured on COOH chip can bind Human EGFR protein, his and Myc tag (CSB-MP007479HU) with an affinity constant of 11.9nM as detected by LSPR Assay.
Measured by its binding ability in a functional ELISA. Immobilized human GCGR at 2 μg/ml can bind Anti-GCGR recombinant antibody (CSB-RA009316A1HU), the EC50 is 3.747-6.666 ng/mL.
Measured by its binding ability in a functional ELISA. Immobilized PD-L1 at 2 μg/ml can bind Anti- PD-L1 mouse monoclonal antibody (CSB-MA878942A1m, antigen from E.coli), the EC50 of human PD-L1 protein is 1.252-1.653 ng/mL
Measured by its binding ability in a functional ELISA. Immobilized HER2 at 2 μg/ml can bind Trastuzumab, the EC50 is 2.179-2.825 ng/ml.
